ELLIOTT-ADVISORS-UK
2.2.2021 08:02:05 CET | Business Wire | Press release
Elliott Advisors (UK) Limited (“Elliott” or “we”), which advises funds that as at the date of this release collectively hold investments equivalent to more than 3% of the share capital of Sampo Oyj (“Sampo” or the “Company”), today published a new presentation outlining a clear pathway to transform Sampo into a pure-play insurer and create in excess of EUR 8 billion of value.
Whilst Sampo’s announcement of 10 November 2020 was a positive first step towards making the structural simplifications necessary to re-establish the Company’s reputation among investors, Sampo’s shares have continued to underperform. Today, Sampo’s high quality core insurance business trades at an unmerited ~5x P/E discount to its peers; this sits in stark contrast to the ~4x P/E premium the business used to trade at several years ago.
Elliott believes that Sampo’s upcoming Capital Markets Day (“CMD”) on 24 February 2021 is the opportune moment for the Company to reverse this historical underperformance and value destruction, highlight its strengths and restore investor confidence. As such, Elliott encourages Sampo to:
- Simplify the Portfolio : Sampo should announce that it plans to become a pure-play insurer by Q4 2021. The Company’s Nordea stake is widely acknowledged to have become a significant distraction and a sustained drag on valuation for Sampo. In a survey of investors commissioned by Elliott, the vast majority of respondents indicated they would like to see a full exit from the Nordea stake within the next twelve months. Sampo is positioned to satisfy investor demands by distributing half of Sampo’s Nordea shares directly to shareholders – an act that over two-thirds of investors surveyed are supportive of – in Q2 2021 and selling the remainder to maintain a healthy balance sheet.
- Clarify the Strategy : Importantly, Sampo should assert that without the overhang of the Nordea stake, the Company will commit to being a dividend-focused P&C insurer, with no material M&A ambitions outside the Nordics until the Hastings deal proves successful. We believe that there is widespread confusion amongst investors about the Sampo equity story, including scepticism on the rationale for the Hastings transaction and Sampo’s future M&A appetite. What is clear is that investors are seeking greater focus on stable dividends, viewed as the lifeblood of a highly rated insurance company, and a commitment by Sampo to become a focused P&C insurer. The stability and growth prospects of IF P&C ideally position Sampo to become the stable dividend payer that investors seek; however, concerns about Sampo’s capital allocation strategy must be resolved before the market can give Sampo the credit it deserves.
- Enhance the Communications : IF P&C is Sampo’s crown jewel. Sampo should clearly and confidently articulate IF P&C’s strong fundamentals and provide the market with relevant, timely and specific targets and KPIs. Shining a spotlight on IF P&C will enable Sampo to recover its premium valuation.
Elliott believes that these measures and the transformation of Sampo into a pure-play insurer would collectively restore investor confidence and unlock in excess of EUR 8 billion in value for Sampo’s shareholders.
Elliott today launched a new website www.SimplifyingSampo.com , where Elliott’s presentation is available to view and download in full. Interested parties are encouraged to visit the website to receive additional information and to sign up for future updates.
About Elliott
Elliott Investment Management L.P. manages approximately $41 billion of assets. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, high net worth individuals and families, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Investment Management L.P.
Disclaimer
Elliott intends to reviews its investments in the company on a continuing basis and depending upon various factors, including without limitation, the company’s financial position and strategic direction, the outcome of any discussions with the company, overall market conditions, other investment opportunities available to Elliott Management, and the availability of company securities at prices that would make the purchase or sale of company securities desirable, Elliott may from time to time (in the open market or in private transactions, including since the inception of Elliott position) buy, sell, cover, hedge or otherwise change the form or substance of any of its investments (including company securities) to any degree in any manner permitted by law and expressly disclaims any obligation to notify others of any such changes. Elliott also reserves the right to take any actions with respect to its investments in the company as it may deem appropriate.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201006050/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 03:00:00 CEST | Press release
Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202627.5.2026 23:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEAOral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei Univ
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 17:22:00 CEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 16:00:00 CEST | Press release
As buyers face tighter budgets, Capchase helps technology companies close more deals faster with AI-enabled instant financing Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks wi
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 15:00:00 CEST | Press release
Annual run-rate revenue more than tripled year-over-year; new CostBench benchmark shows ClickHouse Cloud at 23x better cost-performance than the nearest cloud data warehouse ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
